[1. Dellinger RH, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Sur-viving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013. Feb;41(2):580-637.10.1097/CCM.0b013e31827e83af23353941]Search in Google Scholar
[2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knauss WA, et al. Defini-tions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55. DOI: 10.1378/chest.101.6.164410.1378/chest.101.6.16441303622]Search in Google Scholar
[3. Matzinger P. The danger model: a renewed sense of self. Science. 2002 Apr 12;296(5566):301-5. DOI: 10.1126/science.107105910.1126/science.107105911951032]Search in Google Scholar
[4. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mito-chondrial DAMPs cause inflammatory responses to injury. Nature. 2010 Mar 4;464(7285):104-7. DOI: 10.1038/nature0878010.1038/nature08780284343720203610]Search in Google Scholar
[5. Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predic-tor of bacteremia and outcome from sepsis. QJM.1996 Jul;89(7):515-22. DOI: 10.1093/qjmed/89.7.51510.1093/qjmed/89.7.5158759492]Search in Google Scholar
[6. Bates DW, Sands K, E. Miller E, Lanken PN, Hibberd PL, Graman PS, et al. Pre-dicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis. 1997 Dec;176(6):1538-51. DOI: 10.1086/51415310.1086/5141539395366]Search in Google Scholar
[7. Bauer M, Reinhart K. Molecular diagnostics of sepsis-- where are we today? Int J Med Microbiol. 2010 Aug;300(6):411-3. DOI: 10.1016/j.ijmm.2010.04.00610.1016/j.ijmm.2010.04.00620510650]Search in Google Scholar
[8. Loonen AJM, de Jager CPC, Tosserams J, Kusters R, Hilbink M, Wever PC, et al. Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit. PLoS ONE 2014. Jan; 9(1):e87135. DOI: 10.1371/journal.pone.008731510.1371/journal.pone.0087315390362324475269]Search in Google Scholar
[9. Reinhart K, Bauer M, Riedermann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012 Oct;25(4):609-34 DOI: 10.1128/CMR.00016-1210.1128/CMR.00016-12348575123034322]Search in Google Scholar
[10. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit. Care. 2010;14(1):R15. DOI: 10.1186/cc887210.1186/cc8872287553020144219]Search in Google Scholar
[11. Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers. 2001 Oct-Dec;16(4):233-9.10.1177/172460080101600402]Search in Google Scholar
[12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Apr;31(4):1250-6. DOI: 10.1097/01. CCM.0000050454.01978.3B10.1097/01]Search in Google Scholar
[13. Hatzistilianou M. Diagnostic and prognostic role of procalcitonin in infections. ScientificWorldJournal. 2010 Oct;10:1941-6. DOI: 10.1100/tsw.2010.18110.1100/tsw.2010.181]Search in Google Scholar
[14. Uzzan B, Cohen R, Nicolas P, Cucherat P, Perret GY. Procalcitonin as a diagnos-tic test for sepsis in critically ill adults and after surgery or trauma: a systematic re-view and meta-analysis. Crit Care Med. 2006 Jul;34(7):1996-2003. DOI: 10.1097/01. CCM.0000226413.54364.3610.1097/01]Search in Google Scholar
[15. Bloos F. Clinical diagnosis of sepsis and the combined use of biomarkers and culture and non-culture-based assays. Methods Mol Biol. 2015;1237:247-60. DOI: 10.1007/978-1-4939-1776-1_1910.1007/978-1-4939-1776-1_19]Search in Google Scholar
[16. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515-8. DOI: 10.1016/0140-6736(93)90277-N10.1016/0140-6736(93)90277-N]Search in Google Scholar
[17. Bopp C, Hofer S, Bouchon A, Zimmermann JB, Martin E, Weigand MA. Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory re-sponse syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. Eur J Anaesthesiol. 2009 Jun;26(6):504-7. DOI: 10.1097/ EJA.0b013e328329afca10.1097/EJA.0b013e328329afca19307971]Search in Google Scholar
[18. Povoa P, Teixeira-Pinto AM, Carneiro AH, Portuguese Community-Acquired Sepsis Study Group SACiUCI. C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-centre prospective observational study. Crit Care. 2011 Jul;15(4):R169. DOI: 10.1186/cc1031310.1186/cc10313338760921762483]Search in Google Scholar
[19. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez- Hoyos M, Santibanez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013 Sep; 39(9):1945-52. DOI: 10.1007/s00134-013-3056-z10.1007/s00134-013-3056-z23949703]Search in Google Scholar
[20. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections - hope for hype? Swiss Med Wkly. 2009 Jun;139(23-24):318-26.]Search in Google Scholar
[21. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, et al. Plasma level of soluble uroki nase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteremia: a prospective cohort study. J Intern Med. 2011 Jul;270(1):32-40. DOI: 10.1111/j.1365-2796.2011.02363.x10.1111/j.1365-2796.2011.02363.x21332843]Search in Google Scholar
[22. Georgescu AM, Azamfirei L. Cell receptors as biomarkers in sepsis pathology. J Rom Anest Terap Int. 2014 April;21(1):45-52.]Search in Google Scholar
[23. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected pa-tients receiving highly active antiretroviral therapy. J Med Virol. 2008 Feb; 80(2):209-16. DOI: 10.1002/ jmv.2111410.1002/jmv.2111418098145]Search in Google Scholar
[24. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, car-diovascular disease, diabetes and mortality in the general population. J Intern Med. 2010 Sep; 268(3):296-308. DOI: 10.1111/j.1365-2796.2010.02252.x10.1111/j.1365-2796.2010.02252.x20561148]Search in Google Scholar
[25. Eugen-Olsen J. suPAR - a future risk marker in bacteremia. J Intern Med. 2011 Jul; 270(1):29-31. DOI: 10.1111/j.1365-2796.2011.02372.x10.1111/j.1365-2796.2011.02372.x21366732]Search in Google Scholar
[26. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ. et al. Use-fulness of suPAR as a biological marker in patients with systemic inflammation or in-fection: a systematic review. Intensive Care Med. 2012 Sep; 38(9):1418-28. DOI: 10.1007/s00134-012-2613-110.1007/s00134-012-2613-1342356822706919]Search in Google Scholar
[27. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill pa-tients. Crit Care. 2011; 15(1):R63. DOI: 10.1186/cc1003710.1186/cc10037322199621324198]Search in Google Scholar
[28. Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012 Jan;5:10:2. DOI: 10.1186/1741-7015-10-210.1186/1741-7015-10-2327554522221662]Search in Google Scholar
[29. Siahanidou T, Margeli A, Tsirogianni C, Charoni S, Giannaki M, Vavourakis E, et al. Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study. Mediators Inflamm. 2014 May;2014:375702.10.1155/2014/375702402698924882949]Search in Google Scholar
[30. Donadello K, Scolletta S, Taccone FS, Covajes C, Santonocito C Cortes DO, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care. 2014 Feb; 29(1):144-9. DOI: 10.1016/j.jcrc.2013.08.00510.1016/j.jcrc.2013.08.00524120089]Search in Google Scholar
[31. Koch A, Tacke F. Why high suPAR is not super-diagnostic prognostic and potential pathogenic properties of a novel biomarker in the ICU. Crit Care. 2011 Dec;15(6):1020. DOI: 10.1186/cc1057710.1186/cc10577338868822182777]Search in Google Scholar
[32. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 Apr;348(16):1546-54 DOI: 10.1056/NEJMoa02213910.1056/NEJMoa02213912700374]Search in Google Scholar
[33. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006 Feb;34(2):344-53. DOI: 10.1097/01. CCM.0000194725.48928.3A10.1097/01]Search in Google Scholar
[34. Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock. 2013 Nov;40(5):358-65. DOI: 10.1097/SHK.0b013e3182a66bd610.1097/SHK.0b013e3182a66bd6380604724088989]Search in Google Scholar
[35. Marshall JC, Reinhart K. International Sepsis Forum. Biomarkers of sepsis. Crit Care Med. 2009 Jul;37(7):2290-8. DOI: 10.1097/CCM.0b013e3181a02afc10.1097/CCM.0b013e3181a02afc19487943]Search in Google Scholar
[36. Pisinger C, Ladelund S, Eugen-Olsen J. Influence of Lifestyle on suPAR Levels. The Inter99 Study; 2012 [http://suparnostic.com/images/stories/3rd_supar_symposium_2012_abstracts_program.pdf:11-11]]Search in Google Scholar
[37. Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, et al. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet Med. 2012 Apr;29(4):479-87. DOI: 10.1111/j.1464-5491.2011.03513.x10.1111/j.1464-5491.2011.03513.x22050462]Search in Google Scholar
[38. http://suparnostic.com/Result-Interpretation. [Accessed on Sep 20th, 2012].]Search in Google Scholar
[39. Lodes U, Bohmeier B, Lippert H, Konig B, Meyer F. PCR-based rapid sepsis di-agnosis effectively guides clinical treatment in patients with new onset of SIRS. Langenbecks Arch Surg. 2012 (Mar);397(3):447-55. DOI: 10.1007/s00423-011-0870-z10.1007/s00423-011-0870-z22109826]Search in Google Scholar
[40. Hoenigl M, Raggam RB, Wagner J, Valentin T, Leitner E, Seeber K, et al. Diag-nostic accuracy of soluble urokinase activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome. Clin Bio-chem. 2013 Feb;46(3):225-9. DOI: 10.1016/j.clinbiochem.2012.11.00410.1016/j.clinbiochem.2012.11.00423159293]Search in Google Scholar
[41. Yilmaz G, Koksal I, Karahan SC, Mentese A. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic in-flammatory response syndrome. Clin Biochem. 2011 Oct;44(14-15):1227-30. DOI: 10.1016/j.clinbiochem. 2011.07.006]Search in Google Scholar
[42. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococ- cus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004 May; 10(5):409-15. DOI: 10.1111/j.1469-0691.2004.00850.x10.1111/j.1469-0691.2004.00850.x15113317]Search in Google Scholar
[43. Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int. 2015 Jan;87(1):210-6. DOI: 10.1038/ ki.2014.19710.1038/ki.2014.19724897037]Search in Google Scholar
[44. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis. 2008 May;27(5):375-83. DOI: 10.1007/ s10096-007-0447-510.1007/s10096-007-0447-518197443]Search in Google Scholar
[45. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migra-tion inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diag-nose infections: a prospective study. Crit Care. 2007;11(2):R38. DOI: 10.1186/cc572310.1186/cc5723220645617362525]Search in Google Scholar
[46. Raggam RB, Wagner J, Pruller F, Grisold A, Leitner E, Zollner-Schwetz I, et al. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome. J Inter Med. 2014 Mar;19. DOI: 10.1111/joim.1223810.1111/joim.1223824645798]Search in Google Scholar
[47. Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococus aure-us bacteremia. Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1417-24. DOI: 10.1007/s10096-011-1236-810.1007/s10096-011-1236-821479972]Search in Google Scholar
[48. Moller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, et al. Macro-phage serum markers in pneumococcal bacteremia: prediction of survival by solu-ble CD163. Crit Care Med. 2006 Oct;34(10):2561-6. DOI: 10.1097/01.CCM.0000239120.32490.AB10.1097/01.CCM.0000239120.32490.AB16915112]Search in Google Scholar
[49. Kaya S, Köksal I, Menteşe A, Sönmez M, Sümer A, Yıldırım SS, et al. The signi-ficance of serum urokinase plasminogen activation receptor (suPAR) in the di-agnosis and follow-up of febrile neutropenic patients with hematologic malignan-cies. Int J Infect Dis. 2013 Nov;17(11):e1056-9. DOI: 10.1016/j.ijid.2013.04.004 10.1016/j.ijid.2013.04.00423742830]Search in Google Scholar